Back to the WireInvesting.com
DevelopingInvesting.com ·
AstraZeneca’s cancer drug gets FDA priority review for gastric cancer
AstraZeneca's cancer drug has reportedly received FDA priority review for gastric cancer, according to the headline only. AstraZeneca is a UK company, so any US impact would come through its ADR listing.
Who is reporting it
- Investing.comfirst at Nov 19, 2026, 7:12 AM ESTRead at Investing.com (opens in a new tab)
- Seeking Alphafirst at Nov 19, 2026, 8:47 AM ESTRead at Seeking Alpha (opens in a new tab)
Story so far
Reported by 2 sources
AstraZeneca reportedly received FDA priority review for a gastric cancer drug, according to Investing.com and Seeking Alpha on November 19, 2026. Seeking Alpha noted that priority review could speed the agency's decision timeline, and the regulatory outcome remains pending.
- Nov 19, 2026, 7:12 AM EST · Investing.com · this storyDevelopingAstraZeneca’s cancer drug gets FDA priority review for gastric cancer
- Nov 19, 2026, 8:47 AM EST · Seeking AlphaDevelopingAstraZeneca wins FDA priority review for gastric cancer therapy
- Nov 19, 2026, 8:47 AM EST · Seeking AlphaDevelopingAstraZeneca wins FDA priority review for gastric cancer therapy
Comments
Log in or create a free account to comment.
No comments yet.
The headline links to the original source; the summary is written by The Market Standard. Nothing here is financial advice.